SCHEMBL17066476

SCHEMBL17066476

COc1ccc(-c2cc(C(F)F)n3nc(-c4ccc(C#N)cc4)cc3n2)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 1/20 0.61
MAPT P10636 5/20 0.55
TP53 P04637 2/20 0.55
TDP1 Q9NUW8 1/20 0.55
FUBP1 Q96AE4 5/20 0.53
TSHR P16473 3/20 0.45
MAPK1 P28482 2/20 0.45
CASP1 P29466 1/20 0.45
PDE4D Q08499 1/20 0.44
FYN P06241 3/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 2/20 0.42
USP2 O75604 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17066463 0.83 MAPT (0.77) MAPTTP53TDP1FUBP1TSHR
SCHEMBL17066242 0.82 PIK3CG (0.69) PIK3CGMAPTTP53TDP1FUBP1
SCHEMBL15550034 0.81 PIK3CG (0.67) PIK3CGMAPTTP53TDP1FUBP1
SCHEMBL15549828 0.74 PIK3CG (0.67) PIK3CGMAPTTP53TDP1FUBP1
SCHEMBL17066458 0.74 PIK3CG (0.58) PIK3CGMAPTTP53TDP1FUBP1
SCHEMBL4054536 0.72 PIK3CD (0.58) PIK3CGFYNMEN1KMT2ABRD4
SCHEMBL15558644 0.71 MAPT (0.70) MAPTTP53TDP1FUBP1TSHR
SCHEMBL15975807 0.67 PIK3CA (0.70) MAPTTSHRMAPK1ALDH1A1MEN1
SCHEMBL6499723 0.66 SYK (0.65) MAPTMAPK1ADORA2AADORA1ALDH1A1
SCHEMBL15559690 0.65 TP53 (0.79) MAPTTP53TDP1FUBP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11130758-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-09-28 US disclosed
US-20200347050-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-11-05 US disclosed
US-10640500-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-05-05 US disclosed
US-9850242-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD (JP) 2017-12-26 US disclosed
US-20160339032-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-11-24 US disclosed
US-9446046-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-09-20 US disclosed
US-20160030430-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-02-04 US disclosed
US-9126999-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10640500-B2 Tetrahydropyrazolopyrimidine compounds SSB, TLR8, TLR9 PIK3CG 974/4885MAPT 4449/4885TP53 1253/4885
US-20160030430-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS SSB, TLR8, TLR9 PIK3CG 1435/4885MAPT 4519/4885TP53 1172/4885
US-20160339032-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS SSB, TLR8, TLR9 PIK3CG 1435/4885MAPT 4519/4885TP53 1172/4885
US-20200347050-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS SSB, TLR8, TLR9 PIK3CG 974/4885MAPT 4449/4885TP53 1253/4885
US-11130758-B2 Tetrahydropyrazolopyrimidine compounds SSB, TLR8, TLR9 PIK3CG 974/4885MAPT 4449/4885TP53 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.